Health
Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients – European Pharmaceutical Review
The ITAC trial will establish if hyperimmune intravenous immunoglobulin (hIVIG) plus remdesivir can improve COVID-19 patient outcomes.
Posted: 9 October 2020 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
A Phase III trial to evaluate the safety, tolerability and efficacy of a combination of the antiviral remdesivir and a highly concentrated solution of SARS-CoV-2 neutralising antibodies in hospitalised adult COVID-19 patients has begun.
The tr…
-
Noosa News18 hours agoWest Coast Eagles draftee Josh Lindsay wants to carry on Troy Selwood’s legacy
-
Noosa News23 hours agoDoorDash offering Aussies free burgers, burritos, pizzas and meal bundles as an end of year treat
-
General19 hours agoLabor to squeeze public service, sparking warnings of job losses
-
Noosa News19 hours agoHunt for suspects after family’s pregnant horse found shot dead on rural Queensland property